Selective PPARδ Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators
Molecules · 02.11.2024 · 29 (21) · 5189
DOI: 10.3390/molecules29215189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 02.11.2024. Verfasst von Hyun-Joung Lim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Diseases Research, Department of Chronic Diseases Convergence, National Institute of Health, Cheongju 28159, Republic of K…. Hauptthemen laut MEDLINE: Lipopolysaccharides, Liver Failure, Acute, Thiazoles, PPAR delta. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF) funded by the MSIP, Korea National Institute of Health intramural research, National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
Inflammation is critical in the development of acute liver failure (ALF). Peroxisome proliferator-activated receptor delta (PPARδ) regulates anti-inflammatory responses and is protective in several diseases such as obesity and cancer. However, the beneficial effects and underlying mechanisms of PPARδ agonist GW501516 in ALF remain unclear. This study investigated the molecular mechanisms underlying the anti-inflammatory effects of GW501516 in macrophages and assessed its protective potential against lipopolysaccharide (LPS)/galactosamine (GalN)-induced ALF. In vivo administration of GW501516 significantly reduced LPS/GalN-induced hepatotoxicity, as evidenced by lower mortality, decreased liver damage, and attenuated secretion of IL-1β, IL-6, and TNF-α. GW501516 treatment also decreased LPS-induced nitric oxide synthase 2 (NOS2) expression and nitric oxide (NO) production in RAW264.7 cells, an effect reversed by PPARδ siRNA. Additionally, GW501516 inhibited LPS-induced phosphorylation of p38 and c-Jun N-terminal kinase (JNK), suggesting that inactivation of these MAPKs contributes to its effects. The secretion of IL-6, TNF-α, and NF-κB DNA-binding activity were also suppressed by GW501516, while the nuclear translocation of the NF-κB p65 subunit was unaffected. In conclusion, our findings suggest that GW501516 exerts protective effects in ALF by inhibiting the production of inflammatory mediators. Therefore, GW501516 may act as a potential agent for developing anti-inflammatory therapies for ALF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Diseases Research, Department of Chronic Diseases Convergence, National Institute of Health, Cheongju 28159, Republic of Korea.
- Department of Bio and Fermentation Convergence Technology, Kookmin University, Seoul 02707, Republic of Korea.
Förderung
- National Research Foundation of Korea (NRF) funded by the MSIP
- Korea National Institute of Health intramural research
- National Research Foundation of Korea (NRF)
- Biomaterials Specialized Graduate Program
- Korea Environmental Industry & Technology Institute (KEITI)
- Ministry of Environment(MOE)
Zitieren
APA
Lim, H. J., & Kwak, H. J. (2024). Selective PPARδ Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators. Molecules, 29(21), 5189. https://doi.org/10.3390/molecules29215189
Vancouver
Lim HJ, Kwak HJ. Selective PPARδ Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators. Molecules. 2024;29(21):5189. doi:10.3390/molecules29215189
BibTeX
@article{Lim2024,
author = {Lim, Hyun-Joung and Kwak, Hyun Jeong},
title = {Selective PPARδ Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators},
journal = {Molecules},
year = {2024},
volume = {29},
number = {21},
pages = {5189},
doi = {10.3390/molecules29215189}
}
EUVIMED